Januvia, Singulair, Advair top sites among primary care docs: study

Share this article:

Web sites for Merck's type 2 diabetes drug Januvia, Merck's asthma and allergy treatment Singulair and GlaxoSmithKline's asthma medication Advair were the top three online product destinations respectively among US primary care doctors in 2007, a new study shows.

Market research firm Manhattan Research, which coordinated the study, said the purpose of the analysis was to better determine the leading online physician destinations based on the satisfaction and number of physician visitors.

“The latest research reveals physician site traffic is spread among product sites of new and early launch stage treatments, those with clinical news coverage, and consistent with years past, products with a significant consumer advertising component,” Manhattan Research president Mark Bard said in a statement.

Rounding out the top 10 pharmaceutical product Web sites among physicians in 2007, ranked by number of US primary care physician visitors, were:

4. Pfizer's smoking-cessation aid Chantix

5. Shire's ADHD treatment Adderall XR 

6. Lilly's type 2 diabetes treatment Byetta

7. Merck's HPV vaccine Gardasil

8. Merck and Schering-Plough's joint-venture cholesterol-lowerer Vytorin

9. GlaxoSmithKline's diabetes treatment Avandia

10. McNeill's ADHD treatment Concerta

“We have seen these product sites evolve into brand gateways with visitation from physicians, healthcare professionals, and consumers and with the majority of the top 10 product sites changing from year-to-year, there is clearly a need among physicians for the most up-to-date product information,” Bard added. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...